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Cerebral amyloid angiopathy (CAA) is typified by the cerebrovascular deposition of amyloid. Currently, there is no
clear understanding of the mechanisms underlying the contribution of CAA to neurodegeneration. Despite the fact
that CAA is highly associated with accumulation of Aβ, other types of amyloids have been shown to associate with
the vasculature. Interestingly, in many cases, vascular amyloidosis is accompanied by significant tau pathology.
However, the contribution of tau to neurodegeneration associated to CAA remains to be determined. We used a
mouse model of Familial Danish Dementia (FDD), a neurodegenerative disease characterized by the accumulation of
Danish amyloid (ADan) in the vasculature, to characterize the contribution of tau to neurodegeneration associated to
CAA. We performed histological and biochemical assays to establish tau modifications associated with CAA in
conjunction with cell-based and electrophysiological assays to determine the role of tau in the synaptic dysfunction
associated with ADan. We demonstrated that ADan aggregates induced hyperphosphorylation and misfolding of tau.
Moreover, in a mouse model for CAA, we observed tau oligomers closely associated to astrocytes in the vicinity
of vascular amyloid deposits. We finally determined that the absence of tau prevents synaptic dysfunction induced by
ADan oligomers. In addition to demonstrating the effect of ADan amyloid on tau misfolding, our results provide
compelling evidence of the role of tau in neurodegeneration associated with ADan-CAA and suggest that decreasing
tau levels could be a feasible approach for the treatment of CAA.
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NeurodegenerationIntroduction
Alzheimer disease (AD), the most common form of
dementia, is characterized by the extracellular deposition
of parenchymal and vascular β-amyloid (Aβ), intracellu-
lar accumulation of tau as neurofibrillary tangles (NFTs),
neuronal cell loss, and significant inflammation [15, 39].
Over the past decades, a major focus of research has
been the understanding of the connection between
parenchymal Aβ, NFT, and neurodegeneration, while the
contribution of vascular pathology to NFT and neuro-
degeneration remains understudied.
Cerebral amyloid angiopathy (CAA) is typified by the
cerebrovascular deposition of amyloid and has a close* Correspondence: clasagna@iu.edu
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distinct. Vascular amyloid accumulation is identified in
an estimated 85–95% of individuals with AD [3, 6], posi-
tioning CAA as one of the strongest vascular contri-
butors to age-related cognitive decline [9, 64]. The
mechanisms responsible for CAA pathogenesis and its
downstream effects on the brain are complex and not
completely understood [12, 66]. Despite the fact that
CAA is highly associated with the accumulation of Aβ
[6], other types of amyloids have been shown to associ-
ate with the vasculature. It has also been reported that
some mutations in the PrP gene may result in the depos-
ition of prion amyloid (APrP) in cerebral vessels
(PrP-CAA) [24]. Furthermore, one of the main neuro-
pathological hallmarks of Familial British Dementia
(FBD) and Familial Danish Dementia (FDD) is the pres-
ence of CAA composed of British-amyloid (ABri) and Da-
nish amyloid (ADan) respectively [22, 61, 63]. Thesele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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scribes a heterogeneous group of biochemically and genet-
ically diverse central nervous system disorders,
characterized by the dynamic accumulation of different
amyloid species in the vasculature.
In many cases, vascular amyloidosis is accompanied by
significant tau pathology [24, 49, 60]. Although different
amyloid peptides are deposited in these conditions,
the tau deposits are antigenically and biochemically
indistinguishable [25, 27, 28, 34, 35]. These findings
support a unifying pathological mechanism in which
vascular accumulation of amyloidogenic peptides trig-
gers a complex pathological cascade leading to tau ac-
cumulation and neurodegeneration.
FDD patients are characterized by the presence of
CAA composed of the 4 kDa ADan in leptomeninges
and vessels of the gray and white matter. Genetic
analysis in patients with FDD revealed the presence of a
10-nucleotide duplication insertion in the 3′-end of the
coding region of the BRI2 gene. The mutation in BRI2
causes a frame-shift in the BRI2 sequence, generating a
ADan precursor protein of 277 amino acids, of which
the ~ 4 kDa Danish amyloid subunit comprises the last
34 amino acids [22]. Cotton wool-like plaques in the
vicinity of blood vessels with amyloid and tau NFTs are
also observed in FDD patients [34]. A mouse model for
Familial Danish Dementia (Tg-FDD) [59] consistently
exhibits CAA primarily in leptomeningeal cerebellar ves-
sels [59] and in large and medium-sized parenchymal
and penetrating vessels of the brain. Neuropathologi-
cally, a robust glial activation is observed in close vicinity
of vascular deposits without the presence of cerebral
hemorrhage [59]. Tau immunoreactive deposits in
neuropil have also been observed in this model [59], yet
the spatial relationship between vascular amyloid
deposits and tau in Tg-FDD mice has not been established.
Overall these observations make FDD and the Tg-FDD
mice a valuable model to study the molecular and cellular
mechanisms underlying the role of tau in the neurode-
generative process associated with CAA.
In the present study, we show that ADan induced the
phosphorylation and misfolding of tau and subsequent
tau-dependent neurotoxicity. Our results suggest that
ADan aggregates could have an effect over tau via two
different and non-excluding pathways, and how the
absence of tau could prevent the synaptic dysfunction




QEKHY) [63] was synthesized by ThermoFisher Scientific
using Fmoc-based Solid Phase Peptide Synthesis and
purified by HPLC. To prepare ADan oligomers, ADanpeptide was resuspended in PBS without calcium and
magnesium to a final concentration of 0.5 mg/mL. The
ADan solution was then stirred at room temperature (RT)
for 48 h. Aliquots were collected at different time points
and stored at − 80 °C. To confirm the formation of ADan
oligomers, Western Blot (WB) analysis was performed
using anti-ADan 1699 antibody (1:1000, developed by
R. Vidal) that was specific for residues 23–34
(FNLFLNSQEKHY) of the ADan amyloid peptide [59]
and the conformational antibody anti-oligomers F11G3
(1:1000, provided by R. Kayed), as previously described [44].
Cell culture, transfection, and oligomers treatment
Human embryonic kidney cells expressing doxycycline
(Dox) inducible full length human tau (2N4R) with
the P301L mutation (HEK P301L) ([16] and
Additional file 1: Figure S1) were cultured in DMEM
(Invitrogen) with 10% fetal bovine serum (Invitrogen),
2 mM glutamine, 100 U/mL penicillin, and 100 μg/mL
streptomycin. 1 μg/mL Dox was added into the cul-
ture media to induce human tau expression 24 h prior
to transfection and ADan oligomer treatment. Human
wild-type (WT) BRI2 and BRI2 bearing the Danish muta-
tion were cloned into a pcDNA3.1 vector (Invitrogen).
The sequences were confirmed by Sanger sequencing. All
plasmids were transfected with Lipofectamine 2000
(Invitrogen) and incubated for 48 h. For ADan oligo-
mer treatment, human Tau expression was induced by
1 μg/mL Dox in HEK P301L cells for 24 h, the cells
were treated with 200 nM ADan oligomers, monomers, or
PBS for 8 h. All measurements were made in triplicates.
Cell toxicity assay
HEK P301L cells were plated at 20,000 cells per well
in 96-well plates with 1 μg/mL Dox for 24 h. Then
the cells were treated with 2.5 μM ADan oligomers,
monomers, or PBS. After incubation for 4 h at 37 °C,
cell viability was assayed using a 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell
proliferation assay kit (Promega) according to the manu-
facturer’s specifications. The MTT assay is a colorimetric
assay for assessing cell metabolic activity, which reflects
the number of viable cells. All measurements were made
in six replicates.
Cell lysate preparation and immunoblot analysis
Cells were washed twice with 0.5 mL PBS and lysed on
ice for 60 min in 80 μLT-PER tissue protein extraction
reagent (ThermoFisher Scientific) supplemented with
Complete protease inhibitors cocktail (Roche). The cell
lysates were then centrifuged at 14,800 rpm for 15min
at 4 °C, the supernatants were analyzed by WB as pre-
viously described [44]. Primary antibodies used were
anti-tau (tau-5, 1:1500, Abcam), anti-ptau Thr231
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(1:1000, provided by Dr. Peter Davies), Anti-BRI2 (1:100,
Santa Cruz Biotech) and Anti-GAPDH (1:10000,
Sigma-Aldrich). Tau oligomers levels were measured
using the anti-tau oligomer antibody T22 (1:1000,
provided by Dr. Rakez Kayed) as previously described [43].Immunocytochemistry
HEK P301L cells were plated on the 12mm
Poly-L-Lysine coated coverslips (Corning BioCoat) in
24-well plates at a density of 62,500 cells per well with
1 μg/mL Dox for 24 h, then cells were transfected with
BRI2 bearing the Danish mutation for 48 h. Then, the
coverslips were briefly rinsed with warm TBS and fixed
with 2% paraformaldehyde for 10 min at RT, then
permeabilized for 5 min with 0.1% Triton X-100. The
samples were blocked for 1 h in 5% goat serum and
incubated overnight (O.N.) at 4 °C with mouse anti-ptau
Thr231 (1:1000, Millipore) and rabbit anti-ADan anti-
body 1699 (1:500). Cells were then washed in TBS, then
incubated with Alexa 488-conjugated goat anti-mouse
antibody (1:700, Invitrogen) and Alexa 568-conjugated
goat anti-rabbit antibody (1:700, Invitrogen) for 1 h at
RT, then washed with TBS and mounted with
Vectashield mounting medium with DAPI (Vector
Laboratories). Samples were examined using a Leica
DMi 8 epifluorescence microscope coupled with the LAS
X program (Leica). For orthogonal images of re-
constructed three-dimensional views a Nikon A1-R Laser
Scanning Confocal Microscope coupled with the NIS
Element Advanced Research software was utilized.Transgenic mouse model
Tg-FDD, wild type C57/BL6J (WT) (JAX stock #000664)
and Tau knock out (Tau−/−) (JAX stock #007251) male
and female mice were used for our experiments, inclu-
ding cellular, biochemical, and immunohistochemistry
(IHC) analyses. The Tg-FDD mouse model [59]
expresses a FDD-associated human mutant BRI2 trans-
gene. Mice were housed at the Indiana University School
of Medicine (IUSM) animal care facility and were main-
tained according to USDA standards (12-h light/dark
cycle, food and water ad libitum), in accordance with the
Guide for the Care and Use of Laboratory Animals
(National Institutes of Health, Bethesda, MD). Animals
were anesthetized and euthanized according to IUSM
Institutional Animal Care and Use Committee-approved
procedures. Tissue was collected from 3 and 18months
old animals (5 mice per genotype). Mice were deeply
anesthetized and perfused transcardially with PBS prior
to decapitation. After sacrifice, brains were removed and
stored at − 80 °C or formalin fixed as previously
described [59].Mouse brain samples preparation and immunoblot
analysis
Tg-FDD and WT (5 mice per genotype) brains were
homogenized at a 1:10 (w/vol) ratio of brain and T-PER
tissue protein extraction reagent with complete protease
inhibitor cocktail (Roche). Samples were then centri-
fuged at 13,200 rpm for 15min at 4 °C. The supernatants
were aliquoted, snap-frozen, and stored at − 80 °C until
analyzed. The T-PER insoluble pellets were resuspended
in 88% formic acid (FA) at one fourth volume of their
brain homogenates, then incubated for 1 h at RT.
Samples were then diluted with distilled water to obtain
the same volume used for brain homogenates. Samples
were then lyophilized for 24 h. Freeze-dried samples
were reconstituted in PBS using the same volume as
brain homogenates, then sonicated for 30 s. Finally,
samples were mixed with sample loading buffer, run on
a NuPAGE 4–12% Bis-Tris protein gel (Invitrogen), and
analyzed by WB. Primary antibodies used were anti-BRI2
(1:100, Santa Cruz Biotech), Tau-5 (1:1500, Abcam),
PHF1 (anti-ptau Ser396/Ser404) (1:1000, gift from Peter
Davies), anti-ptau Thr231 (1:1500, Abcam), MC1 (1:100,
gift from Peter Davies), and anti-Vinculin (1:10000,
Invitrogen). Secondary antibodies used: goat anti-mouse
HRP IgG (1:1500, Invitrogen) and goat anti-rabbit HRP
IgG (1:1500, Invitrogen). WB quantification results are
expressed as the ratio of phospho-tau to total tau levels.
Then this value was normalized by the loading control.
In all cases, we considered the control group as the
100%. For the FA treated samples, equal amount of pro-
teins were loaded, previously determined by Bradford
assay (ThermoFisher Scientific) according to manufac-
turer’s specification.
Brain sections immunofluorescence (IF)
Paraffin sections were deparaffinized in xylene and rehy-
drated in ethanol (EtOH) and washed with deionized
water. Then the sections were heated with a microwave
oven in low pH antigen retrieval solution (eBioscience)
twice for 4 min each. After washing in TBS twice for 5
min each, the sections were blocked in 5% normal goat
serum for 1 h at RT, sections were incubated O.N. at 4 °C
with the following antibodies: anti-ADan 1699 (1:500),
T22 (1:100, gift from Dr. Rakez Kayed), TOMA (1:750, gift
from Dr. Rakez Kayed), MC1 (1:750, gift from Dr. Peter
Davies), anti-GFAP antibody (1:200, Sigma-Aldrich),
anti-Iba1 (1:250, Millipore), and NeuN (1:100, Abcam).
For amyloid detection, sections were first stained with 1%
Thioflavin S (Thio-S) in TBS for 8min before the primary
antibody incubation, then washed in EtOH and deionized
water. The next day, the sections were washed in TBS
and incubated with secondary antibodies Alexa
488-conjugated goat anti-mouse antibody (1:500,
Invitrogen) and Alexa 568-conjugated goat anti-rabbit
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sections were washed in TBS and mounted with
Vectashield mounting medium with DAPI (Vector
Laboratories). For colocalization analysis we utilized the
Coloc 2 plugin from Fiji that implements and performs
the pixel intensity correlation over space methods of
Pearson [55]. For every single staining, as a negative
control, primary antibodies were omitted to determine
background and autofluorescence (not shown). WT and
Tg-FDD cerebral cortex was examined using a Leica DMi
8 epifluorescence microscope coupled with the LAS X
program (Leica).
Quantitative PCR
Mouse brains total RNA were isolated with RNeasy Plus
Universal Mini kit (Qiagen). cDNA was prepared from
1 μg total RNA with High-Capacity cDNA reverse
transcription kit (Life Technologies). All qPCRs were
performed on QuantStudio 6 Flex Real-Time PCR
system (Life Technologies). The mouse Mapt relative
gene expression was evaluated with delta Ct method
using Taqman probe sets (Mapt: Mm00521988_m1,
GAPDH: 4351309, Life Technologies) and TaqMan
Universal PCR Master Mix.
Brain slice preparation
Immediately following euthanasia via decapitation
under deep isoflurane anesthesia, the brain was quickly
excised and placed in an ice-cold tissue cutting solution
containing (in mM): 194 sucrose, 30 NaCl, 4.5 KCl, 1
MgCl2, 26 NaHCO3, 1.2 NaH2PO4, 10 Glucose saturated
with a mixture of 95% O2 and 5% CO2, and sliced to a
thickness of 280 μm on a vibratome (Leica VT1200S,
Germany). Slices were transferred to an artificial cerebro-
spinal fluid (aCSF) solution containing (in mM): 124 NaCl,
4.5 KCl, 1 MgCl2, 26 NaHCO3, 1.2 NaH2PO4, 10 Glucose,
2 CaCl2 (310–320 mOsm) saturated with 95% O2/5%
CO2 at 30 °C for 1 h before being moved to RT. When
ready for recording, in control conditions, slices were
transferred to a recording chamber continuously perfused
with aCSF solution saturated with 95% O2/5% CO2. In
experiments using the ADan oligomer, the slices were first
transferred to an incubation chamber containing aCSF
containing 400 nM ADan oligomer saturated with 95%
O2/5% CO2 at RT for at least 1 h before being trans-
ferred to the recording chamber.
Primary cerebellar granule neurons culture and
immunofluorescence
Cerebellums were obtained from 8 to 10 days old mouse
pups from WT C57/BL6J (JAX stock #000664) and Tau
knock out (JAX stock #007251) mice. Their brains were
dissected, the cerebellum separated, cleaned thoroughly
from meninges, and incubated with 0.25% trypsin EDTAand 25mg/mL DNase. Then they were disaggregated by
passing them through a 221/2 G syringe needle pre-
viously coated with 100 mg/mL BSA in ultrapure cell
culture grade water. The suspension was centrifuged for
5 min at 1250 rpm, and then cells were resuspended in 8
mg/mL BSA. A second centrifugation was followed by a
resuspension in 2 mg/mL BSA. Finally, cells were resus-
pended a third time in primary granule neuron media
(1X Neurobasal medium, Invitrogen) and counted. They
were seeded in 24-well plates that contained coverslips
previously treated with 0.01% poly-L-lysine. Seeding
number was 50,000 cells/well. After 14 days in vitro
(DIV), cells were fixed for 15 min at 37 °C in a solution
of 4% paraformaldehyde/sucrose in TBS. Cells were
washed with TBS, permeabilized with 0.25% Triton
X-100 in TBS, and blocked with 10% BSA in TBS.
Primary antibodies anti-Synapsin 1 (1:100, Abcam) and
anti-PSD95 (1:100, Abcam) were incubated O.N. at 4 °C.
The next day cells were washed in TBS, permeabilized in
0.25% Triton X-100, and incubated with secondary anti-
bodies Alexa Fluor-488 anti-mouse (1:100, Invitrogen)
and Alexa Fluor-568 anti-rabbit (1:100, Invitrogen) for 1 h
at RT. Finally, cells were washed in TBS for 3 min,
mounted with Vectashield mounting medium with DAPI,
and visualized using a Leica DMi 8 epifluorescence
microscope coupled with the LAS X program (Leica).
Clusters of Synapsin 1 and PSD95 were quantified as
previously described [14].
Field potential recordings
Field excitatory postsynaptic potential (fEPSP) recor-
dings from the stratum radiatum of hippocampal area
CA1 were carried out at 29–32 °C and aCSF was
continuously perfused at a rate of 1–2 ml/minute using
a Multiclamp 700B amplifier (Axon Instruments, Union
City, CA) signals were amplified (gain 100) and filtered
(1 kHz), then digitized (10 kHz). Slices were visualized on
an Olympus BX51WI microscope (Olympus Corporation
of America). Picrotoxin (50 μM) was added to the
aCSF for recordings to isolate excitatory potentials.
Micropipettes were prepared from filament-containing
borosilicate micropipettes (World Precision Instruments)
using a P-1000 micropipette puller (Sutter Instruments,
Novato, CA), having a 2.0–3.5MΩ resistance. The glass
micropipettes were filled with 1M NaCl and placed into
the stratum radiatum of hippocampal area CA1. A con-
centric bipolar stimulating electrode (FHC, Bowdoin, ME)
was placed into stratum radiatum in area CA1 ∼ 500 μm
from the recording site. fEPSPs were generated by a DS3
Isolated Current Stimulator (Digitimer, Ft. Lauderdale, FL)
every 20 s and stimulus intensity was adjusted to produce
stable fEPSP responses prior to the initiation of experi-
mental recording. A 10min baseline was recoded before
delivery of four high frequency stimulations (HFS; 100 Hz,
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acquired using Clampex 10.3 (Molecular Devices,
Sunnyvale, CA). The representative traces were obtained
from the average baseline fEPSP (1–10min) and average
post-HFS fEPSP of the final 10min of recording.
Exclusion of individual data points was determined using
an outlier calculator included in the Prism 7 software
package. Recordings were made 2–7 h after euthanasia.
The analysis of fEPSP slopes were used to determine the
effects of ADan oligomer. The experimenter was not
blinded to treatments administered to the slices.
Statistical analyses
Experimental analysis and data collection were performed
in a blinded fashion, if not stated otherwise. P values were
determined using the appropriate statistical method via
GraphPad Prism, as described throughout the manuscript.
Statistical comparisons were made using two-tailed
unpaired Student’s t-test with Welch’s correction,
Mann-Whitney test or one-Way ANOVA with Tukey’s
correction. Figures 1b, 2d, 3b-d, and 8C use unpaired
Student’s t-test follow by Welch’s correction. Figure 7b-d
use Mann-Whitney test and Fig. 2c use one-Way ANOVA
followed by Tukey’s correction. Data are presented as
mean ± SD if not stated otherwise. *, **, ***, and ****
denote P < 0.05, P < 0.01, P < 0.001, and P < 0.0001
respectively. All details of experiments can be found in the
Results or the Figure Legends.
Results
The ADan peptide leads to hyperphosphorylation of tau
FDD patients are not only characterized by the vascular
accumulation of ADan amyloid, but also by the accumu-
lation of hyperphosphorylated tau. Therefore, we decided
to determine in a cellular model if ADan promotes tau
hyperphosphorylation. To do so, we transfected BRI2
bearing the Danish mutation in HEK cells, lacking
endogenous tau, that conditionally express human tau
with the P301L mutation after the addition of Dox [16].
As a control, we transfected WT BRI2. Danish mutant
BRI2 overexpression led to an increase in the levels of
phosphorylated tau at Ser396/Ser404 and Thr231
(Fig. 1a-b). To determine if the effect of ADan aggre-
gates over tau phosphorylation and aggregation is
mediated by a direct interaction between ADan peptides
and tau or by an indirect mechanism, we performed
double-immunostaining using an anti-ADan antibody
and an anti-phospho tau antibody (Thr231). We
observed colocalization of ADan immunoreactivity
with phospho-tau Thr231 in a number of cases, but
this was not observed in all cases (Fig. 1c). Overall,
these results suggested that the expression of BRI2
bearing the Danish mutation could induce the aggre-
gation and phosphorylation of tau, a process that, incell culture, could be mediated by a direct event or
by an indirect mechanism.
ADan oligomers promote tau phosphorylation and
toxicity by a mechanism that is tau dependent
Since BRI2 is a transmembrane protein and the Danish
mutation induced the secretion of the ADan peptide to
the extracellular space [22] (Additional file 1: Figure S2),
we evaluated the effect of ADan monomers and oligo-
mers over tau phosphorylation and cellular toxicity. To
test this, we prepared ADan recombinant oligomers as
we previously described [44]. Figure 2a shows the for-
mation of ADan oligomers immunoreactive with the
conformational anti-oligomer F11G3 antibody after 48 h
of stirring. Incubation of ADan oligomers or mono-
mers with HEK cells that conditionally express mutant
tau for 8 h showed that when cells are exposed to
ADan oligomers, tau becomes hyperphosphorylated
(Fig. 2b-c). These ADan oligomers and even mono-
mers, in a lower degree, are able to get internalized
into the cells (Additional file 1: Figure S3). Moreover,
cells treated with oligomers for 4 h showed a signifi-
cant cellular toxicity as measured by the MTT cell pro-
liferation assay (Fig. 2d). Surprisingly, ADan oligomer
toxicity was only observed when cells were induced to
express human tau after the addition of Dox, but not
when cells did not express it (Fig. 2d). Overall, these
results suggest that ADan oligomers could induce tau
hyperphosphorylation and subsequent tau-dependent
toxicity.
Accumulation of endogenous murine tau in a mouse
model for familial Danish dementia
We tested whether ADan aggregates affect endogenous
murine tau phosphorylation in vivo in the Tg-FDD
model, which is characterized by ADan amyloid deposits
in the vasculature [59] (Additional file 1: Figure S4). WB
analysis of soluble brain fractions showed a significant
increase in phosphorylated tau at Ser396/Ser404 and
Thr231 in 18months old Tg-FDD mice compared to
WT controls of the same ages (Fig. 3a-c). No changes in
the levels of phosphorylated tau at Ser202/Thr205,
Ser214, Ser262 and Ser356 were observed (data not
shown). When we performed WB analysis using the
MC1 antibody that recognizes early stages of tau
misfolding, we observed a significant increase in
MC1-positive tau (Fig. 3a and d), suggesting that the
accumulation of vascular amyloid in the Tg-FDD model
promotes murine tau misfolding. Quantification of
murine tau mRNA levels did not show any differences
between Tg-FDD and WT mice (Fig. 3e), demonstrating
that the effect of ADan amyloid in the Tg-FDD model
over tau is at the protein level. We then performed bio-
chemical characterizations of the insoluble brain
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these fractions demonstrated the presence of insoluble
ADan in the Tg-FDD mice (Fig. 3f ), but not tau (Fig.
3f ) or phospho-tau (data not shown), suggesting that in
the Tg-FDD model endogenous murine tau does not
accumulate into insoluble aggregates. Interestingly,
whenever we performed WB analysis of soluble brain
fractions from 3months old Tg-FDD mice, an age
when no vascular amyloid is observed [59], noFig. 1 Expression of BRI2 bearing the Danish mutation promotes tau phosph
with WT BRI2 or mutant BRI2. b Graph showing WB quantification of p-tau S39
analysis; *p = 0.0372, Unpaired Student’s t test. For p-tau T231 analysis; *p = 0.0
represented ± SD (n = 3). Values of phospho-tau/total tau ratio in cells transfe
reconstructed three-dimensional views of p-tau T231 (green) and ADan (red)
with mutant BRI2. Left panels shows staining with anti-p-tau T231 antibody (g
right panels shows the merge of both signals, DAPI staining (blue) for nucleu
panel, indicate ADan inclusions that colocalize with p-tau T231. In bottom pa
with p-tau T231. Scale bar 15 μmchanges in the level of phosphorylated tau were observed
(Additional file 1: Figure S5). Overall, these results suggest
that vascular amyloid accumulation possibly induces
endogenous tau phosphorylation and misfolding.
To confirm the amyloidogenic nature of ADan
deposits in the vasculature of the Tg-FDD model, we
double stained brain sections of 18 months old mice
with the ADan antibody and Thio-S. We observed that
ADan deposition in the cerebral vessels was mainlyorylation. a WB analysis of lysates from HEK tau-P301L cells transfected
6/S404/total tau and p-tau T231/total tau ratio. For p-tau S396/S404
455, Unpaired Student’s t test. For both quantifications error bars
cted with WT BRI2 were considered as 100%. c Orthogonal images of
by confocal images of HEK cells expressing human tau-P301L transfected
reen), middle panels show staining with anti-ADan antibody (red), and
s plus cross-sectional images X-Z and Y-Z. Cross-sectional image in top
nel, cross-sectional image indicates ADan inclusions that don’t colocalize
Fig. 2 ADan oligomers promoted tau phosphorylation and cellular toxicity that is tau dependent. a WB using anti-ADan antibody revealed the
formation of multimers from ADan recombinant peptide after 2, 8, 24, and 48 h of stirring. WB using the conformational anti-oligomers antibody
F11G3 confirmed the formation of ADan recombinant oligomers after 48 h of stirring. HMW= High Molecular Weight, LMW = Low Molecular
Weight. b WB analysis of lysates from HEK tau-P301L cells exposed to PBS, ADan monomer or oligomers. c Graph showing WB quantification of
p-tau S396/S404/ total tau ratio. For p-tau S396/S404 analysis; *p < 0.05, One-way ANOVA with Turkey’s correction. For quantification, error bars
represented ± SD (n = 3). Values of phospho-tau S396/S404/total tau ratio in cells treated with PBS were considered as 100%. d Cytotoxicity
exerted by ADan oligomers in cells, measured by MTT reduction, depends on human tau-P301L expression induced by Dox. For PBS-oligomer
analysis in (Dox+); *p < 0.0001, Unpaired Student’s t test. For monomer-oligomer analysis in (Dox+); *p < 0.0001, Unpaired Student’s t test. For
quantifications, error bars represented ± SEM (n = 6). MTT values were originally obtained as absorbance at 570 nm. For graphic purposes, MTT
reduction in cells treated with PBS were considered as 100%
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sitions negative for Thio-S were also observed (Fig. 4a-c).
To determine the presence of ADan soluble
aggregates, such as oligomers, we performed double
immunofluorescence in brain sections using the ADan
antibody and the conformation specific monoclonal
anti-oligomer F11G3 antibody (Fig. 4d-f ) [31, 44].
Substantial intracellular co-localization between both
antibody signals was observed (Fig. 4f ).
We performed double immunofluorescence in adjacent
sections using anti-ADan and MC1 or TOMA antibodies
to assess the spatial relationship between vascular ADan
deposits and tau. Both MC1 and TOMA antibodies recog-
nized early stages of tau aggregation such as oligomers
[11, 37]. Double staining of anti-ADan and TOMA on
Tg-FDD sections showed the accumulation of tau oligo-
mers in the vicinity of vessels enriched with amyloid de-
posits in the cortex (Fig. 5a, top and bottom panel).
Double staining of anti-ADan and MC1 confirmed the
presence of misfolded tau surrounding ADan-positive ves-
sels (Fig. 5b, top panel). Interestingly, double staining of
anti-ADan and MC1 also revealed intracellular association
between ADan and MC1-positive tau in the cerebral cor-
tex (Fig. 5b, bottom panel). Overall these resultsdemonstrated the presence of two types of pathological
accumulation of tau in this CAA model. One where mis-
folded tau accumulates in the vicinity of vessels enriched
with ADan deposits, and a second one where misfolded
tau co-localized with ADan intracellular signal in areas
of the cerebral cortex, where no major vascular amyloid
deposits are observed. Tau oligomers were observed in
other brain regions (Additional file 1: Figure S6) that
have been previous associated with the accumulation of
vascular amyloid in this mouse model [59].
Tau oligomeric deposits in the vicinity of vascular
amyloid are closely associated with astrocytic profile
Innate immunity is activated both in cerebrovascular
disease [38] and in AD. In the context of our CAA model,
we observed severe astro and microgliosis, as evidenced by
robust GFAP and Iba1 staining in areas affected by ADan
amyloid vascular deposits (Additional file 1: Figure S7).
Based on this observation, we decided to determine
which cell type showed tau oligomers associated with vas-
cular amyloid. We performed triple immunofluorescence
in Tg-FDD brain sections for Thio-S (amyloid), T22 (tau
oligomers), and GFAP or Iba1 or NeuN for astrocytes,
microglia, or neurons, respectively. Fluorescent
Fig. 3 Tau hyperphosphorylation and misfolding in Tg-FDD mice. a WB analysis of brain lysate from WT and Tg-FDD 18months old mice. WB
using anti-BRI2 antibody was performed to confirm mice genotypes and Vinculin was used as a loading control. b Graph showing WB
quantification of p-tau S396/S404/total tau ratio. ****p < 0.0001, Unpaired Student’s t test. c Graph showing WB quantification of p-tau T231/total
tau ratio. ****p < 0.0001, Unpaired Student’s t test. d Graph showing WB quantification of MC1 tau/total tau ratio. ****p < 0.0001, Unpaired
Student’s t test. For all three quantifications (b-d) error bars represented ± SD (n = 5). Values from WT mice were considered as 100%. (e)
Endogenous murine tau mRNA levels measured by qRT-PCR did not change in Tg-FDD mice in comparison with WT mice (n = 5). f WB analysis of
brain insoluble fractions from WT and Tg-FDD demonstrated the presence of ADan insoluble aggregates in Tg-FDD detected using the anti-ADan
antibody (left blot). No tau (using tau-5 antibody) was detected in the insoluble fraction neither from WT nor Tg-FDD mice (right blot)
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ated with GFAP-positive astrocytes (Fig. 6a-e).
Co-localization analysis between T22 and GFAP signal
suggest that these oligomers are located in the cytoplasm
and astrocytic processes (Fig. 6e). Triple staining with
Thio-S, T22, and Iba1 showed that tau oligomers were not
associated with Iba1-positive microglia (Fig. 6f-j). Interest-
ingly, triple staining revealed that tau oligomers are
associated with neurons in areas throughout the cor-
tex where no Thio-S-positive vascular structures were
located (Fig. 6k-o). Substantial co-localization betweenT22 and NeuN antibody signals was observed (Fig.
6o).
Tau is required for ADan-induced impairment of the
structure and function of neuronal synapses
It is widely accepted that the adverse effects of Aβ on
neuronal degeneration and cognitive dysfunction appear
to depend largely on soluble tau [29]. For instance, it has
been reported that the reduction of tau expression
prevents Aβ-induced neurodegeneration in cell culture
[51, 65]. Moreover, in vivo studies have shown how
Fig. 4 Amyloid characterization in Tg-FDD mice. a-c Double immunofluorescence using anti-ADan antibody (a, red) and Thio-S (b, green) in brain
sections of Tg-FDD mice confirm the presence of Thio-S-positive ADan amyloid in the vasculature (c, Merge). e-f Double immunofluorescence
using anti-ADan antibody (e, red) and the anti-oligomer antibody F11G3 (f, green) in brain sections of Tg-FDD mice confirm the presence of
ADan oligomers in the cortex (f, Merge). Both are representative images of the cerebral cortex of 18 months old Tg-FD mice. Scale bar 20 μm
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mouse model prevents behavioral deficits without alter-
ing the amount of Aβ plaques in the parenchyma [54].
Therefore, considering these previous studies, in addition
to the fact that a decrease in the levels of synaptic markers
in Tg-FDD mice has been reported [23], we aimed to
investigate if the neuronal damage triggered by ADan, a
highly vasculotropic amyloid, is also dependent on tau.
To investigate if ADan aggregates induce impairment
of the synaptic structure via tau, we performed IF for theFig. 5 Spatial relationship between tau oligomers and ADan deposits in Tg
(green) in the vicinity of ADan vascular amyloid detected by anti-ADan ant
(green) around ADan vascular amyloid (red). Bottom panel shows intracellular l
All figures were obtained from 18months old Tg-FDD mice cerebral cortex. Scpre- and post-synaptic markers Synapsin-1 and PSD95
respectively, and assessed their localization at synapses
in cultured primary cerebellar granule neurons from
WT mice and mice with a genetic knock-out of Mapt
gene (Tau−/−) in the presence or absence of ADan
oligomers (Fig. 7a). Our results show a decrease in the
total number of clusters or puncta marked for Synapsin-1
and PSD95 in WT neurons incubated with 500 nM of
ADan oligomers in comparison with untreated WT
control groups. Remarkably, ADan oligomers did not have-FDD mice. a Accumulation of tau oligomers detected by TOMA
ibody (red). b Top panel shows accumulation of MC1-positive tau
ocalization of ADan deposits (red) and MC1 tau (green) immunoreactivity.
ale bar 15 μm
Fig. 6 Tau oligomers cell specificity in Tg-FDD mice. a-e Fluorescent microscopic images of Tg-FDD brain section triple immunostaining for
amyloid (Thio-S, green), Tau oligomers (T22, red), and astrocytes (GFAP, cyan). Tau oligomers immunoreactivity showed close association with
astrocytes and astrocytic processes (Merge). Colocalization analysis (CC) was performed to determine pixel intensity correlation between T22 and
GFAP signals. White pixels indicate colocalization between T22 and GFAP signal (e, white pixels). f-j Triple immunostaining for amyloid (Thio-S,
green), Tau oligomers (T22, red), and microglia (Iba1, cyan). Tau oligomers are not associated to microglia surrounding vascular amyloid (Merge).
Colocalization analysis confirmed the lack of correlation between T22 and Iba1 signal (j). k-o Triple immunostaining for amyloid (Thio-S, green),
Tau oligomers (T22, red), and neurons (NeuN, cyan). Tau oligomers were found associated to neurons in areas where vascular amyloid was not
detected. White pixels indicate colocalization between T22 and NeuN signal (o, white pixels). All figures were obtained from 18 months
old Tg-FDD mice cerebral cortex. Scale bar 25 μm
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Synapsin-1 or PSD95 on Tau−/− neurons (Fig. 7b-c). ADan
oligomers not only affected the number of Synapsin-1 and
PSD95 clusters in WT neurons, but also has a detrimental
effect on the colocalization between these pre- and
post-synaptic markers. On the other hand, no effect on
the synaptic colocalization between Synapsin-1 and
PSD-95 was observed in Tau−/− neurons after the addition
of ADan oligomers (Fig. 7d). To correlate these results
with a functional analysis, we performed hippocampal
long-term potentiation (LTP) experiments in hippocampal
area CA1 in WT and Tau−/− mouse-derived brain slice
preparations. We monitored fEPSPs evoked by extracellu-
lar stimulation of the Schaffer collateral pathway and
induced LTP using high-frequency stimulation (four
stimuli of 100 Hz for 1 s with a 10 s inter-stimulus
interval). In WT slices pretreated with 400 nM ADan
oligomers for 2 h, LTP was almost completely blocked
(Fig. 8a and c). This was a specific effect of ADan oligo-
mers, because control slices showed LTP (Fig. 8a and c).These results demonstrate that, in WT mice, acute
application of ADan impairs one or more of the cellular
mechanisms necessary for LTP. To confirm a possible
functional interaction between ADan and tau, we tested
the effect of ADan oligomers on LTP in Tau−/− mice.
Slices incubated in the control solution showed normal
levels of LTP and, remarkably, slices preincubated in
ADan oligomers showed LTP levels of similar magnitude
(Fig. 8b-c).
Overall, these results indicate that the absence of tau
could prevent the synaptic dysfunction induced by a
CAA-associated amyloid such as ADan.Discussion
The data reported here shows that ADan amyloid
peptide, the amyloid responsible for wide spread CAA in
FDD patients, induces the phosphorylation and mis-
folding of tau in vitro and in vivo. We also demonstrated
that ADan oligomers exert cellular toxicity and
Fig. 7 ADan oligomers do not alter the number and localization of synaptic proteins in Tau−/− mice derived cerebellar granule neurons. a
Representative immunofluorescence photographs for clusters of the synaptic proteins Synapsin-1 (red), PSD95 (green), and their colocalization
(yellow) in cerebellar granule neuronal dendrites. Four experimental groups were analyzed: WT and Tau−/− neurons in the presence or absence of
ADan oligomers (+ADan, b-d) Graphs showing the quantification of positive ((+)) clusters for each marker and their colocalization per 100 μm of
dendrite. The number of cells analyzed was 15 per each culture, from 3 independent cultures. Results are shown as the mean ± SEM of n = 3.
Asterisks indicate significant differences, where * p < 0.05 and *** p < 0.001 by Mann-Whitney test. Scale bar = 10 μm
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dependent manner.
Previous studies reported the existence of several
neurodegenerative diseases characterized by vascular
amyloid deposition known as CAA [52, 58]. Among
CAAs, Aβ-CAA is the most common and is frequently
present in AD [42]. Other examples include the accumu-
lation of vascular ADan amyloid or ABri amyloid in
patients with Familial Danish Dementia and Familial
British Dementia, respectively [61, 63]. Vascular accu-
mulation of amyloidogenic forms of Cystatin C, Gelsolin,
Transthyretin, and prion protein are pathologicalFig. 8 ADan oligomers do not reduce LTP in slices of Tau−/− mice. a ADan
collateral-CA1 LTP in WT mice in control (circles) or after incubation with A
baseline fEPSP (1–10min) and average fEPSP of the final 10 min of recordin
CA1 LTP in Tau−/− mice in control (circles) or after incubation with ADan o
Tau−/− mice. The inset shows superimposed example traces before and 40
average of normalized fEPSP slope for final 10 min of recording (40–50 min
Unpaired Student’s t test; n = 8 slices Ctrl from 4 mice, n = 6 slices ADan ol
Unpaired Student’s t test; n = 7 slices Ctrl from 4 mice, n = 8 slices ADan olhallmarks of Hereditary cystatin C amyloid angiopathy,
Familial amyloidosis Finnish type, Familial transthyretin
amyloidosis (FTA)-leptomeningeal form and prion
protein-CAA, respectively [18, 24, 45, 52, 62]. Interest-
ingly, in some forms of CAA, glial activation and aggre-
gated tau deposits are present, suggesting an important
role for inflammation and tau accumulation in
neurodegeneration associated with vascular amyloid de-
position, as has been previously suggested for parenchy-
mal amyloid accumulation [8, 57].
Noteworthy, several studies have suggested that
pathologic changes of tau in neurons can impactoligomers reduce LTP in slices of WT mice. Hippocampal Schaffer
Dan oligomers (squares). Representative traces are the average
g (40–50 min) for each condition. b Hippocampal Schaffer collateral-
ligomers (squares). ADan oligomers do not reduce LTP in slices of
min after high-frequency stimulation for each condition. c Data show
) relative to 10min baseline average. For WT; p = 0.0007, t12 = 4.537,
igomer (400 nM) from 4 mice. For Tau−/−; p = 0.9440, t13 = 0.0716,
igomer (400 nM) from 4 mice
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the brain’s microvasculature [5, 47]. For instance, it has
been shown that vessel wall remodeling of leptomeningeal
arteries is an early-onset, tau pathology-dependent
process, which may potentially contribute to downstream
CAA-dependent microvascular pathology in AD patients
[47]. Even more, other studies have demonstrated an
increase of BBB permeability and the accumulation of tau
oligomers in the cerebral microvasculature of human
patients with progressive supranuclear palsy (PSP) [4, 10],
emphasizing the role of tau aggregates in the functional
and structural integrity of the cerebral vasculature. In a
similar fashion, tau-overexpressing mice develop
changes to blood vessels including abnormal, spiraling
morphologies; reduced blood vessel diameter; and
increased overall blood vessel density in the cortex
[5]. Also, in a different mouse model for tauopathies,
BBB dysfunction emerges at the same time that peri-
vascular tau emerges around major hippocampal
blood vessels. However, when tau expression is
suppressed, BBB integrity is preserved, suggesting that
the BBB can be stabilized in a tauopathic brain by
reducing tau levels [7]. Overall, these studies strongly
suggest that in relation to vascular damage, tau aggre-
gation is not a unidirectional event where vascular
damage initiates a series of events that triggers tau
aggregation, but is rather a vicious cycle where tau
pathology enhances vascular damage.
In Tg-FDD mice, expression of the Danish mutant
form of BRI2 driven by the moPrnp promoter is suffi-
cient for the development of CAA, suggesting that neural
cells are the source of the cerebrovascular amyloid and
highlighting the vasculotropic nature of the ADan peptide
[59]. In the present study, we confirmed the presence of a
robust activation of micro and astroglia surrounding vas-
cular ADan deposits in Tg-FDD mice. We biochemically
demonstrated an increase of hyperphosphorylated forms
of tau in the Tg-FDD. This increase was only observed in
certain phospho-tau epitopes, but not others that have
been associated to tau NFTs in AD, suggesting that the
process of tau hyperphosphorylation associated to CAA
deposits could be different from the hyperphosphorylation
of tau associated to parenchymal deposition of amyloid.
We also showed the presence of tau oligomers in peri-
vascular regions, in the vicinity of ADan amyloid deposits,
as well as in areas throughout the cerebral cortex. Based
on our observations, at least in the context of FDD, we
proposed a dual-mechanism of action with vascular
amyloid deposits resulting in tau hyperphosphory-
lation/aggregation and subsequent neurodegeneration:
1) Indirect mechanism is where ADan peptides
secreted from neurons accumulate around vascular
vessels. Subsequently, vascular amyloidaccumulation triggers perivascular astrogliosis and
astrocytic tau oligomerization. Interestingly,
astrocytes play a key role in maintaining the BBB
via astrocytic end feet directly opposed to vascular
endothelial cells [50], and tau has been shown to
accumulate in these end feet in tauopathies [36, 41],
including perivascular astrocytic tau deposits in
CAA patients [60]. These results suggest that
vascular damage, due to amyloid accumulation,
could induce an astrocytic response that triggers
tau misfolding.
In addition to maintaining BBB integrity, astrocytes
also modulate synaptic function by the secretion and
uptake of neurotransmitters such as glutamate [32].
Considering this, plus a recent description of a fronto-
temporal dementia variant that displayed reduced
glutamate transporter-1 staining in a subset of tau-bearing
astrocytes [21], and also that the sole presence of tau in
astrocytes in a mouse model for tauopathies produces a
significant decrease in glutamate transport capacity [17];
we can speculate that the decrease in synaptic markers
observed in the Tg-FDD mouse model could be due
to astrocytic dysfunction triggered by tau oligomers.
Nevertheless, considering novel studies where the role
of glia in relation to tau spreading is described [2,
46], we cannot rule out the propagation of tau oligo-
mers from the astrocytes to neurons as a source of
synaptic function disturbance in the Tg-FDD model.
2) Direct mechanism is where ADan peptide, cleaved
from transmembrane neuronal BRI2, forms amyloid
oligomers and is internalized by neurons. These
intraneuronal aggregates could directly induce the
aggregation of endogenous tau by a cross-seeding
event that subsequently promotes synaptic dysfunc-
tion. A similar mechanism has been suggested for
Aβ and alpha-synuclein, in which both amyloids
interact with tau via an interface to co-aggregate
into hybrid oligomers [31, 56]. We cannot exclude
the possibility that the intraneuronal ADan could
co-aggregate with tau in the Tg-FDD due to the
neuronal over-expression of mutant BRI2 rather
than a CAA specific phenotype. Nevertheless, it has
been previously reported that Aβ40, an amyloid
highly associated with Aβ-CAA, can also form
intraneuronal inclusions [30], suggesting that
CAA-associated amyloids could also contribute to
neurodegeneration via the formation of neuronal
aggregates.
Overall, both proposed mechanisms enhance the
relevance of tau in the pathogenesis associated to CAA.
This is highly relevant considering a novel patient-based
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pivotal role in cognitive impairment in patients with
subcortical vascular cognitive impairment (SCVI),
suggesting that tau could represent a common pathway
for dementia triggered by both cerebrovascular and
parenchymal amyloid pathologies [40].
Previous studies have shown how endogenous WT tau
appears to be required for parenchymal Aβ-amyloid
accumulation and ApoE4 to cause synaptic, network,
and cognitive deficits in mouse models of AD [1, 53, 54].
Tau ablation has also been shown to attenuate motor
abnormalities in a Huntington’s disease (HD) mouse
model [20] and prevent deficits in spatial learning and
memory after repeated mild frontal impact in WT mice
[13]. Even more, tau reduction has the ability to block
epileptogenesis of diverse causes, including epileptic
activity triggered by pharmacological blockade of GABAA
channels [19, 54], genetic ablation of the voltage-gated
potassium channel subunit Kv1.1 [33], depletion of
ethanolamine kinase or of the K+–Cl− cotransporter [33],
or depletion of the voltage-gated sodium channel subunit
Nav1.1 [26]. The mechanisms underlying these beneficial
effects of tau reduction remain to be determined [48]. As
mentioned above, recent evidence suggest that tau could
be involved in a common pathway for neurodegeneration
triggered by cerebrovascular abnormalities and paren-
chymal amyloid pathologies [40]. Thus, our findings
that demonstrated how ADan amyloid aggregates
required endogenous tau expression to exert cell death;
synaptic and LTP impairment lead us to suggest that
partial tau reduction could be considered a feasible
approach for the treatment of dementias associated with
CAA, at least in the context of FDD.Conclusions
Previous efforts in AD and AD-related dementias
have aimed to understand the connection between
parenchymal amyloid, tau aggregation, and neuro-
degeneration, with the contribution of vascular amyloid
pathology to tau aggregation and neurodegeneration
remaining understudied. To the best of our knowledge,
this is the first study aiming to understand, in detail,
the connection between vascular amyloid deposition
and tau pathology. Using a set of in vitro and in vivo
approaches, we proposed the existence of two
possible mechanisms of how ADan vascular amyloid
may trigger tau misfolding. Even more, the fact that
tau reduction was sufficient to prevent neuronal
synaptotoxicity due to the presence of ADan oligo-
mers, an amyloid highly associated to vascular
deposits substantiates, at least in FDD, tau level modu-
lation as an effective therapeutic target for neurodegene-
ration associated with CAA.Additional file
Additional file 1: Figure S1. Doxycycline-inducible cell line expressing
human mutant P301L tau. Western blot of cell lysate probed with Tau-5
antibody confirming the expression of tau induced by Dox. Figure S2.
BRI2 processing in Familial Danish Dementia. Processing of mutant BRI2
by pro-protein convertases (PCs) generates the 34 amino acid peptide
(ADan) and a mature form of BRI2 (m-BRI2). Processing by ADAM10 in
the ectodomain of BRI2 releases the BRICHOS domain and an N-terminal
fragment. Disulfide bonded loops in the BRICHOS domain and in the
carboxy-terminus of BRI2 are indicated. Figure S3. ADan oligomers and
monomers are internalized in HEK cells. Orthogonal images of
reconstructed three-dimensional views of ADan (red) and nucleus (blue)
by confocal images of HEK tau-P301L cells. ADan oligomers are
internalized and accumulated intracellularly (right image). In a lower
degree than oligomers, ADan monomers are internalized into cells too
(middle image). PBS treated cells were utilized as negative controls.
Figure S4. CAA in a transgenic mouse model for FDD: Thio-S detection
of leptomeningeal and cortical blood vessels in the cerebellum and
cortex of Tg-FDD mice. Figure S5. Young Tg-FDD mice do not show
changes in tau. (A) Western blot of brain from 3 months old WT and Tg-
FDD mice. (B) Graph showing WB quantification of p-tau S396/S404.
Figure S6. Tau oligomers in Tg-FDD mice. IF using the TOMA antibody
(green) revealed the presence of tau oligomers in the hippocampus,
cortex, and cerebellum of 18 months old Tg-FDD mice. MC1-positive
staining was also observed in the hippocampus, cortex, and cerebellum
of these mice. Tau-/- was utilized as control. Figure S7. Glial activation
associated to CAA. (A-F) IF of ADan amyloid (red) and GFAP (green) in
Tg-FDD (A-C) and WT (D-F). (G-L) IF of ADan amyloid (red) and Iba1
(green) in Tg-FDD (G-I) and WT (J-L). Scale bar 25 μm. (DOCX 10546 kb)
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